Previous 10 | Next 10 |
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
2024-04-30 11:51:08 ET More on Alkermes Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data Alkermes plc: Collecting The Fruits Of The 2023 Spinoff Alkermes plc 2023 Q4 - Results - Earnings Call Presentation Alkermes posts early-stage win for s...
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 PR Newswire DUBLIN , April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a pha...
Alkermes to Report First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, Ma...
2024-04-16 16:24:42 ET Summary The healthcare sector is overvalued by 14% based on 11-year averages. Healthcare providers are not far from their valuation baseline, while the most overvalued subsector is healthcare equipment. Fast facts on Fidelity MSCI Health Care Index ETF, ...
2024-04-10 09:00:04 ET Akash Tewari from Jefferies issued a price target of $50.00 for ALKS on 2024-04-10 07:44:00. The adjusted price target was set to $50.00. At the time of the announcement, ALKS was trading at $26.73. The overall price target consensus is at $31.33 w...
2024-04-09 16:29:10 ET Summary Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and idiopathic hypersomnia, with significant efficacy and manageable side effects. The company plans to proceed with a Phase 2 study for ALKS-2680 in Narcolepsy Type 2 later this y...
2024-04-09 15:15:03 ET UBS analyst issues BUY recommendation for ALKS on April 9, 2024 01:01PM ET. The previous analyst recommendation was Buy. ALKS was trading at $26.765 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst r...
2024-04-09 13:30:01 ET Jefferies analyst issues BUY recommendation for ALKS on April 9, 2024 12:04PM ET. The previous analyst recommendation was Buy. ALKS was trading at $27 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst...
2024-04-09 13:00:03 ET Akash Tewari from Jefferies issued a price target of $25.00 for ALKS on 2024-04-09 12:04:00. The adjusted price target was set to $25.00. At the time of the announcement, ALKS was trading at $26.95. The overall price target consensus is at $32.00 w...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...